Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Atypical hemolytic uremic syndrome and eculizumab therapy in children

  • Kim, Seong Heon (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Kim, Hye Young (Department of Pediatrics, Pusan National University Hospital) ;
  • Kim, Su Young (Department of Pediatrics, Pusan National University Children's Hospital)
  • Received : 2017.12.07
  • Accepted : 2018.01.25
  • Published : 2018.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating disorder that progressively damages systemic organs, resulting in stroke, end-stage renal disease, and death. The traditional treatment for aHUS is mainly plasmapheresis or plasma infusion; however, many children with aHUS will progress to chronic kidney disease despite plasma therapy. Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Currently, several guidelines for aHUS, including the Korean guideline, recommend eculizumab as the first-line therapy in children with aHUS. Moreover, life-long eculizumab therapy is generally recommended. Further studies on discontinuation of eculizumab are needed.

Keywords

References

  1. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. https://doi.org/10.1007/s00281-014-0416-x
  2. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-87. https://doi.org/10.1056/NEJMra0902814
  3. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46. https://doi.org/10.1046/j.1523-1755.2001.060003831.x
  4. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312-22. https://doi.org/10.1111/jth.13571
  5. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8:554-62. https://doi.org/10.2215/CJN.04760512
  6. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013;33:508-30. https://doi.org/10.1016/j.semnephrol.2013.08.003
  7. Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015; 57:431-8. https://doi.org/10.1111/ped.12549
  8. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63. https://doi.org/10.1681/ASN.2004050380
  9. Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol 2012;7:417-26. https://doi.org/10.2215/CJN.05750611
  10. Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012;27:1283-91. https://doi.org/10.1007/s00467-012-2131-y
  11. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-59. https://doi.org/10.2215/CJN.02210310
  12. Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, et al. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol 2017; 18:6. https://doi.org/10.1186/s12882-016-0420-6
  13. Azukaitis K, Loirat C, Malina M, Adomaitiene I, Jankauskiene A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1273-7. https://doi.org/10.1007/s00467-013-2713-3
  14. Brandt J, Wong C, Mihm S, Roberts J, Smith J, Brewer E, et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 2002;110(2 Pt 1):371-6. https://doi.org/10.1542/peds.110.2.371
  15. Espie E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, et al. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006. Pediatr Infect Dis J 2008;27:595-601. https://doi.org/10.1097/INF.0b013e31816a062f
  16. Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int 2016;58:549-55. https://doi.org/10.1111/ped.13044
  17. Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 2016;31:1516-28. https://doi.org/10.3346/jkms.2016.31.10.1516
  18. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016;31:15-39. https://doi.org/10.1007/s00467-015-3076-8
  19. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403. https://doi.org/10.1056/NEJM199108083250605
  20. Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78. https://doi.org/10.1007/s00467-014-2817-4
  21. Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004;19:454-8. https://doi.org/10.1007/s00467-003-1371-2
  22. Cho H, Lee Y. Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutation. Clin Nephrol 2017;88:52-6. https://doi.org/10.5414/CN109138
  23. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13:663-75. https://doi.org/10.1111/ajt.12077
  24. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008;22:65-74. https://doi.org/10.1016/j.blre.2007.10.002
  25. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8. https://doi.org/10.1182/blood-2007-06-095646
  26. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. https://doi.org/10.1182/blood-2014-09-600411
  27. Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 2016;68:84-93. https://doi.org/10.1053/j.ajkd.2015.12.034
  28. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81. https://doi.org/10.1056/NEJMoa1208981
  29. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015; 87:1061-73. https://doi.org/10.1038/ki.2014.423
  30. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701-11. https://doi.org/10.1016/j.kint.2015.11.026
  31. Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014;63:40-8. https://doi.org/10.1053/j.ajkd.2013.07.011
  32. Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 2017;12:50-9. https://doi.org/10.2215/CJN.06440616
  33. Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 2017;10:310-9.
  34. Hackl A, Ehren R, Kirschfink M, Zipfel PF, Beck BB, Weber LT, et al. Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS. Pediatr Nephrol 2017;32:1081-7. https://doi.org/10.1007/s00467-017-3612-9
  35. Sahutoglu T, Basturk T, Sakaci T, Koc Y, Ahbap E, Sevinc M, et al. Can eculizumab be discontinued in aHUS?: case report and review of the literature. Medicine (Baltimore) 2016;95:e4330. https://doi.org/10.1097/MD.0000000000004330
  36. Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract 2016;4:1066-75. https://doi.org/10.1016/j.jaip.2016.09.012